Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review.
Calixto GM, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M. · 2016
Read Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review. by Calixto GM, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6274468.txt.
Introduction
Calixto and co-authors review nano carriers that deliver light activated cancer drugs. Their review appeared in Molecules. The treatment is photodynamic therapy. A drug settles in the tumour, then light of the right colour activates it. The active drug harms the tumour and its blood supply. Many such drugs dissolve poorly in water, which limits their use.
Loading the drug into nano carriers can fix that flaw. Carriers range from polymer particles and fat based particles to gold particles and gels. They can also help drugs cross cell barriers. Two drugs can ride in one carrier for a joint attack. The review weighs each carrier type for strengths and limits. It maps a fast growing route to stronger cancer care.
Catalog record
| CREATOR | Calixto GM, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review By Giovana Maria Fioramonti Calixto, Jéssica Bernegossi, Laura Marise de Freitas, Carla Raquel Fontana, Marlus Chorilli, Alexandru Mihai Grumezescu Published in: Molecules DOI: 10.3390/molecules21030342 ABSTRACT Photodynamic therapy (PDT) is a promising alternative approach for improved cancer treatment. In PDT, a photosensitizer (PS) is administered that can be activated by light of a specific wavelength, which causes selective damage to the tumor and its surrounding vasculature. The success of PDT is limited by the difficulty in administering photosensitizers (PSs) with low water solubility, which compromises the clinical use of several molecules. Incorporation of PSs in nanostructured drug delivery systems, such as polymeric nanoparticles (PNPs), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), gold nanoparticles (AuNPs), hydrogels, liposomes, liquid crystals, dendrimers, and cyclodextrin is a potential strategy to overcome this difficulty. Additionally, nanotechnology-based drug delivery systems may improve the transcytosis of a PS across epithelial and endothelial barriers and afford the simultaneous co-delivery of two or more drugs. Based on this, the application of nanotechnology in medicine may offer numerous exciting possibilities in cancer treatment and improve the efficacy of available therapeutics. Therefore, the aim of this paper is to review nanotechnology-based drug delivery systems for photodynamic therapy of cancer. 1. INTRODUCTION The combination of dyes and light for treatment of diseases dates back to ancient Egypt, where conditions such as psoriasis and vitiligo were treated with vegetal-derived substances and sunlight [1]. However, it was only in the beginning of 20th century that modern PDT (photodynamic therapy) began with the discoveries of O. Raab [2] and H. von Tappeiner and A. Jesionek [3]. O. Raab observed the deleterious effect of treating Paramecium caudatum with acridine orange and accidentally exposing it to sunlight [2]. In 1903, von Tappeiner and Jesionek reported the tumoricidal effect of eosin associated with exposure to the white light on skin tumors. They conceived the term “photodynamic action” [3]. PDT is considered a promising alternative treatment modality to current treatments against several types of cancers. A non-toxic dye (capable of transferring light energy to other molecules, i.e., a photosensitizing agent) is administered to the patients with subsequent exposure to a light source of specific wavelength that leads to the death of the target cell via oxidative damage [4]. Three components act simultaneously in PDT: a photosensitizer (PS), a light source, and oxygen. The PS and light source must be harmless to the target cell [5]. When the PS is excited by light of a specific wavelength, its interactions with the surroundings can follow two pathways. These pathways are named Type I and Type II reactions, as illustrated in Figure 1. In type I reactions, the PS in its excited triplet state reacts with biomolecules (i.e., lipids, proteins, and nucleic acids), transferring hydrogen atoms via the radical mechanism. It generates free radicals and radical ions (radical type depends on the target molecule, i.e., lipids, proteins, or nucleic acids) that then react with oxygen resulting in reactive oxygen species (ROS) generation [6,7,8,9]. Type II reactions are based on a phenomenon called triplet–triplet annihilation. In these reactions, the PS in its excited triplet state reacts with oxygen in its triplet ground state. This yields singlet oxygen that is highly reactive and cytotoxic. Both types of reactions take place at the same time. The balance between these two processes depends on the PS being used, the concentrations of oxygen and substrate, and affinity of the PS with the substrate [6,7,8,9]. However, singlet oxygen generation pathway i.e., Type II reactions are considered the principal mechanism of [10]. ROS and singlet oxygen have high reactivity and short half-life. Due to this, PDT directly affects only those biological substrates that are close to the region where these species are generated, usually within a 20 nanometers radius [11]. Therefore, PS localization is a primary factor in drug release studies to target tissues because it selectivity promotes localized sensitization. 2. CLINICAL PDT AGAINST CANCER Although the discovery of photodynamic effect was based in the field of microbiology, the use of PDT against microbial infections was severely cutback after the introduction of antibiotics in the 1940s. However, it is being revisited in the last few decades as an alternative therapy due to the increasing bacterial resistance to existing antibiotics [6]. PDT advancements occurred primarily for the treatment of cancer and non-infectious diseases, such as vitiligo, macular degeneration, and psoriasis [12]. Various clinical protocols have been approved for the treatment of pre-malignant and malignant lesions since its introduction in clinical practice in the 1980s [7,8]. The cancer types treated using PDT include cancers of the digestive tract [13,14] and esophagus [15,16], lesions of the head and neck [17], lung and malignant pleural mesothelioma [18], cervix, bladder, and non-melanoma skin cancer, and basocellular carcinoma [8], among others. Clinical PDT protocol usually includes a standard dose of the drug, a dose from a light source, and a drug-light interval. However, the clinical outcomes may vary enormously. This is probably due to poor light delivery to the target tissue, resistance to the drugs (e.g., in tumors), or metabolism of the PS in individual patients [19]. Light delivery can be enhanced by using deeper wavelengths (from 600 to 800 nm, the “therapeutic window”) [20,21] or a different illumination approach, such as interstitial instead of superficial light delivery [22]. PDT-resistant tumor cells were isolated in vitro. The mechanisms of resistance to PS are similar to those described for general drugs, including increased drug inactivation, decreased uptake, drug efflux, and altered intracellular trafficking [23]. The combination of at least two different treatment modalities is one of the strategies to overcome tumor resistance. For example, combination of PDT and chemotherapy was extremely efficient in eliminating cancer cells as shown by our group [21] and others [24,25,26]. PDT has several advantages over conventional cancer treatment approaches. First generation PSs cause minor self-limited photosensitivity to the eyes and skin; however, PDT has no long-term side effects when properly used [27]. It is less invasive than surgical procedures and the side effects usually last for a shorter period than chemotherapy or radiotherapy. Furthermore, PDT procedures are most often performed on an outpatient basis. Moreover, it also destroys the vasculature associated with the tumor besides the tumor itself, which contributes greatly to tumor death [11]. Furthermore, PDT can be directed to a target tissue very precisely due to its dual selectivity (only the irradiated area receives the PS and the light simultaneously). It can be repeated several times at one location if necessary, unlike radiation. There is little or no scarring after healing. Lastly, it generally costs less than other cancer treatments [28]. However, like every therapy, PDT has some limitations. The photodynamic effect takes place selectively at the irradiated site, which makes it impossible for PDT to be used in disseminated metastases with currently available technology, and this does not allow for a whole body irradiation with the appropriate light intensity [28]. Tissue and tumor oxygenation is crucial for the photodynamic effect to take place; therefore, tumors surrounded by necrotic tissue or dense tumor masses lead to impaired PDT. Finally, the likelihood of the precise light delivery to the target tissues is the most important point when considering PDT